Marksans Pharma Limited — PPTs, 26-05-2026: Investor Presentation

**1. Business Performance:** Marksans Pharma posted a record FY26, hitting total income of ₹3,033 Cr (+12.8% YoY) and net profit of ₹420 Cr. Q4FY26 revenue surged 20.8% YoY to ₹856.1 Cr, with net profit up 64.3% YoY to ₹149 Cr. Growth was robust in US & North America (+24% YoY FY26), Australia & New Zealand (+61% YoY Q4), and the UK saw a strong Q4 recovery.

**2. Growth Drivers or Strategy:** The company prioritizes its high-growth OTC segment, leveraging a 200+ product pipeline for 20-25 new launches annually. Marksans also seeks strategic front-end acquisitions in Europe, backed by its healthy ₹990 Cr cash balance.

**3. Recent Developments:** Key updates include 112 new SKUs in the US and market entry into Germany, Canada, and Ireland. Australia's Nova Pharma division launched 11 new Rx branded products. Annual manufacturing capacity now stands at 26 billion units.

**4. Key Financial Metrics:** FY26: Total Income ₹3,033 Cr; Net Profit ₹420 Cr; Diluted EPS ₹9.2. Q4FY26: Revenue ₹856.1 Cr; Net Profit ₹149 Cr.

**5. Management Commentary / Outlook:** Management is confident, noting the major capex cycle is concluding. Marksans aims to become a top global consumer healthcare company by FY30, focusing on sustained growth through deeper market penetration and geographic expansion.